Leveraging the selective replication of VSV in tumor cells and expression of NY-ESO-1 in tumor cells, combining NY-ESO-1 expression with NY-ESO-1 TCR-T cell therapy has the potential to activate specific immune responses and overcome the limitations of current NY-ESO-1-targeted therapies due to heterogeneous antigen expression, thereby offering potential therapeutic benefits for such cancer patients. The gene discussed is CTAG1B; the disease is neoplasm.